Key result
Novel pharmacologic and nonpharmacologic therapies provide new strategies for cardiovascular disease prevention.
This review provides an overview of evolving pharmacologic, nonpharmacologic, and strategic approaches to cardiovascular disease prevention.
The purpose of this review is to describe novel pharmacologic and nonpharmacologic preventive therapies, as well as new strategies to improve delivery of available therapies. Cardiovascular disease (CVD) is the leading cause of death worldwide, and prevention plays a critical role in curbing the global epidemic. Despite available treatment for tobacco addiction, platelet inhibition, blood pressure, and lipid lowering for reduction of atherosclerotic disease, significant gaps in treatment of total CVD remain. We review a range of new preventive treatment options, including drugs for tobacco cessation, platelet/thrombotic inhibition, lipid- and blood pressure-lowering; nonpharmacologic options such as left atrial appendage closure devices and caloric restriction; and strategies such as fixed-dose combination drugs, laboratory screening for drug tailoring, and community-based prevention programs. CVD preventive research continues to evolve and provide clinicians and patients with novel pharmacologic and nonpharmacologic therapies, including new preventive strategies.
No takes yet. Share an insight, caveat, or question.
Huffman et al. (2011) conducted a review in Cardiovascular disease. Novel pharmacologic and nonpharmacologic preventive therapies was evaluated. Cardiovascular disease preventive research continues to evolve, providing clinicians and patients with novel pharmacologic and nonpharmacologic therapies and new preventive strategies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: